Bharat Biotech asked to submit complete ph 2 data of its COVID-19 vaccine before ph 3 trial
The company has applied to the Drugs Controller General of India (DCGI) on October 2, seeking its permission to conduct phase-3 randomised double-blind placebo-controlled multicentre trial of its COVID-19 vaccine candidate.
No hay comentarios:
Publicar un comentario